Renovo Equine Allograft Logo
  • Home
  • About
    • Our Company
    • Product
    • Team RenoVō®
    • Key Opinion Leader, Dr. Bree Valensin
    • News
  • Product
    • RenoVō®
    • FAQs
    • Studies
      • Clinical Studies
      • Case Studies
    • Manufacturing
    • Disclaimer
  • Case Studies
  • Clinical Studies
  • Find a Vet
  • Order
    • Order RenoVō®
    • Shop Merch
  • Contact
RenoVō® vs PRP vs IRAP vs Stem Cells: Understanding Equine Regenerative Options

RenoVō® vs PRP vs IRAP vs Stem Cells: Understanding Equine Regenerative Options

Nov 3, 2026 | Clinical Study, News

When a horse experiences a tendon injury, joint inflammation, or other tissue related condition, veterinarians have several regenerative therapy options to consider. PRP, IRAP, and stem cell therapy are all autologous options, which means each one is made from the...
Why Are Equine Vets Choosing RenoVō® Over PRP and Stem Cell Therapy?

Why Are Equine Vets Choosing RenoVō® Over PRP and Stem Cell Therapy?

Aug 6, 2026 | Clinical Study, News

If you have searched for an alternative to PRP, IRAP, or stem cell therapy for a horse that is not responding to care, you have probably come across RenoVō®. It is a liquid, acellular equine amniotic tissue allograft that supplements and protects tissue, and it is...
RenoVō® CASE STUDY: Bilateral Corneal Ulcers

RenoVō® CASE STUDY: Bilateral Corneal Ulcers

Oct 29, 2024 | News

Supporting Equine Sarcoid Management: RenoVō® Case Study

Supporting Equine Sarcoid Management: RenoVō® Case Study

Oct 8, 2024 | Event, News

Categories

  • Case Study
  • Clinical Study
  • Event
  • News
  • Press Release

Do you want more information about RenoVō®?

For inquiries. you may call us at 501-708-5000 or at [email protected]

Contact Us

Home      About      Product      Testimonials      News      Contact      Distributors

Renovo Logo

Copyright © | Equine Amnio Solutions. All rights reserved.

RenoVō® is a Registered Trademark of Equine Amnio Solutions, LLC

Privacy Policy    Terms of Use

Subscribe To Our Monthly Emails
  • Follow
  • Follow
  • Follow